Faricimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | VEGF-A, angiopoietin 2 |
| Clinical data | |
| Other names | RO6867461 |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| UNII | |
| KEGG | |
Faricimab (INN[1]) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.
This drug is being developed by Hoffmann-La Roche. As of 2018, faricimab is undergoing Phase III trials.
References[]
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs